skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes

(2810) Views  (658) Full article downloads

Authors: Baptist Gallwitz

Published Date May 2007 Volume 2007:3(2) Pages 203 - 210
DOI: http://dx.doi.org/10.2147/VHRM.S

Baptist Gallwitz

Dept. Medicine IV, Eberhard Karls University, Tuebingen, Germany

Abstract: Sitagliptin (Januvia®, Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor) that has recently been approved for the therapy of type 2 diabetes. Like other DPP-4 inhibitors its action is mediated by increasing levels of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). Sitagliptin is effective in lowering HbA1c, and fasting as well as postprandial glucose in monotherapy and in combination with other oral antidiabetic agents. It stimulates insulin secretion when hyperglycemia is present and inhibits glucagon secretion. In clinical studies it is weight neutral. This article gives an overview of the mechanism of action, the pharmacology, and the clinical efficacy and safety of sitagliptin in type 2 diabetes therapy.

Keywords: incretins, type 2 diabetes, diabetes therapy, DPP-4 inhibitors, sitagliptin








Readers of this article also read:
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University